Dorjimae is Sorafenib tosylate tablets. Sorafenib tosylate tablets and lenvatinib can not be taken at the same time, and it is necessary to choose the best one according to the patient’s condition and under the guidance of professional doctors. 1. Sorafenib tosylate tablets are indicated for the treatment of inoperable advanced renal cell carcinoma, the treatment of inoperable or distant metastatic hepatocellular carcinoma, the treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer. The most common adverse reactions were diarrhea, rash, alopecia, and skin reactions of the hands and feet. It is contraindicated in patients with severe allergic symptoms to sorafenib or the inactive ingredients of the drug. It is contraindicated in pregnant and lactating women. 2. Lenvatinib, as a targeted drug, is mainly indicated for patients with unresectable hepatocellular carcinoma who have not received previous systemic systemic therapy, i.e. patients with advanced hepatocellular carcinoma. Its major side effects include hypertension, proteinuria, hand-foot syndrome, fever, rash, diarrhea, malaise and other symptoms. It should be contraindicated in people who are allergic to any of the components of the product, and lenvatinib mesylate should not be used during pregnancy. During the treatment with the drug, if any discomfort occurs, consult a doctor in time to avoid adverse consequences.